Handok strengthens partnership with Alexion through renewal and new agreements

Published: 2016-11-22 13:32:27

Updated: 2016-11-22 13:32:27

On the 17^th, Handok(Chairman Young-Jin Kim) and U.S. Alexion Pharmaceuticals(CEO David L. Hallal) renewed the agreement of Soliris and signed a Korean sales agreement of rare disease therapies, ‘Strensiq’ and ‘Kanuma,’ to strengthen their strategic partnership.

Handok started the partnership with Alexion in 2009, the Soliris’s successful commercialization and their win-win partnership had led ...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.